Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Kura Oncology, Inc.
Dren Bio
Incyte Corporation
Quetzal Therapeutics
AVM Biotechnology Inc
Orca Biosystems, Inc.
Kura Oncology, Inc.
Novartis
Kura Oncology, Inc.
Arovella Therapeutics Ltd
Taiho Oncology, Inc.
CRISPR Therapeutics
AstraZeneca
AvenCell Therapeutics, Inc.
Takeda
Daiichi Sankyo
Vironexis Biotherapeutics Inc.
Novartis
Pfizer
Fate Therapeutics
Syndax Pharmaceuticals
Takeda
Kura Oncology, Inc.
Incyte Corporation
Allogene Therapeutics
BeOne Medicines
Ossium Health, Inc.
Ossium Health, Inc.
Celgene
GeoVax, Inc.
Novartis
Incyte Corporation
NextCure, Inc.
Adela, Inc
AstraZeneca
Acerta Pharma BV
Amgen
SDK Therapeutics, Inc.
AbbVie
First Ascent Biomedical Inc.
AbbVie
Daiichi Sankyo
Servier
Nerviano Medical Sciences
Massive Bio, Inc.
CRISPR Therapeutics
Incyte Corporation
Constellation Pharmaceuticals
AbbVie